何慶財(cái)

[關(guān)鍵詞] 冠心病;曲美他嗪;阿托伐他汀; hs-CRP;TNF-α

[中圖分類號(hào)] R541.4? ? ? ? ? [文獻(xiàn)標(biāo)識(shí)碼] A? ? ? ? ? [文章編號(hào)] 1673-9701（2021）20-0005-04

The effect of trimetazidine combined with atorvastatin in the treatment of patients with coronary heart disease and its influence on the levels of hs-CRP and TNF-α

HE Qingcai

Department of Emergency，the Eighth People's Hospital of Dongguan City in Guangdong Province，Dongguan? ?523325，China

[Abstract] Objective To investigate the effect of trimetazidine combined with atorvastatin in the treatment of patients with coronary heart disease and its influence on the levels of hs-CRP and TNF-α. Methods A total of 112 patients with coronary heart disease admitted to our hospital from July 2017 to July 2018 were selected and divided into two groups by lottery. Both groups were treated with conventional treatment. The control group was treated with atorvastatin on the basis of conventional treatment. The study group was treated with trimetazidine on the basis of the control group. The levels of inflammatory factors，endothelial function，blood lipids，cardiac function，and adverse reaction indexes of the two groups were observed and compared. Results The levels of hs-CRP，TNF-α，MMP-9 and MDA in the study group after treatment were lower than those in the control group，with significant difference （P<0.05）. The ET-1 after treatment in the study group was lower than that in the control group，with significant difference （P<0.05）. The NO and cEMPs after treatment in the study group were higher than those in the control group，with significant difference（P<0.05）. The LDL-C and TC levels in the study group after treatment were lower than those in the control group， with significant difference （P<0.05）. After treatment， the LVEF and LVDD indexes in the study group were higher than those in the control group， with significant difference （P<0.05）. The total incidence of adverse reactions in the study group was lower than that in the control group， with significant difference （P<0.05）. Conclusion In the treatment of coronary heart disease，trimetazidine combined with atorvastatin has a significant therapeutic effect，which can effectively reduce the levels of inflammatory factors such as hs-CRP and TNF-α. It is clinically worthy of increasing promotion and application.

[Key words] Coronary heart disease; Trimetazidine; Atorvastatin; hs-CRP; TNF-α